Rajat Bannerji MD PhD

Hematologic Oncology

Professor, Medicine, Rutgers Robert Wood Johnson Medical School

195 Little Albany StNew Brunswick, NJ 08901
Phone+1 732-235-7996
Fax+1 732-448-7894

Dr. Bannerji is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bannerji's full profile Already have an account?

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1998 - 2001
Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
Weill Cornell MedicineClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 2006 - 2027
NY State Medical License 2006 - 2008
PA State Medical License 1998 - 2008
American Board of Internal Medicine Hematology

Clinical Trials

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2020 May 06
WITHDRAWN
PHASE2

Publications & Presentations

PubMed

1 citations
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies.
Yingxue Chen, Renli Teng, Attila Szanto, Apoorva Kapopara, Rajat Bannerji
Clinical Pharmacology in Drug Development. 2025-07-01
11 citations
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Sam Yuen, Tycel J Phillips, Rajat Bannerji, Paula Marlton, Giuseppe Gritti
American Journal of Hematology. 2024-07-01
117 citations
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji
Blood. 2024-04-18

Abstracts/Posters

Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

FDA Pushes Pause on 2 Regeneron Lymphoma Trials for Cytokine Release SyndromeDecember 15th, 2020
$Durable Responses Seen with Odronextamab in Refractory B-cell NHLs$
Durable Responses Seen with Odronextamab in Refractory B-cell NHLsDecember 7th, 2020
REGN1979 Shows Good Activity in Pretreated Aggressive B-NHLJanuary 15th, 2020